News

In August, Corcept said that the first of its trials for Corlux had failed. Corlux is Corcept’s lead product in development. The primary endpoint of the study was

In its letter to the company, the FDA indicated that Labopharm’s once-daily formulation of tramadol is approvable subject to clearing up some deficiencies in the application, which Labopharm

Under the terms of the agreement, TAP will be responsible for promoting Famvir to the Obstetrician and Gynecology medical community. Famvir is the first and only oral antiviral

These trials were conducted to investigate the safety, tolerability and pharmacokinetics of intravenous and intramuscular injections of peramivir in healthy volunteers. The company said that in additional studies

The Hart-Scott-Rodino waiting period for the Barr’s acquisition of Shire’s Adderall expired without further action from the US Federal Trade Commission. As a result, the product acquisition agreement

The agreement will attempt to determine whether GelVac is adaptable for delivering human papillomavirus virus (HPV)vaccines in a powder dosage form for mucosal immunization. In June the FDA

Zanamivir is the active ingredient in Relenza which was developed by GSK under license from Biota Holdings. “This agreement with Simcere is intended to expand available supplies of

The deal is subject to the approval of the product by Health Canada. Atripla is the first once-daily single tablet regimen for HIV intended as a stand-alone therapy

The study was designed to evaluate patient adherence to long-term treatments for multiple sclerosis in a real-world setting. Non-adherence was defined as missing at least one injection or